At the last check today, the stock’s price was $35.96, to imply an increase of 20.83% or $6.2 in intraday trading. A high-level overview of Cullinan Oncology, Inc. (CGEM) stock. View today's stock price, news and analysis for Cullinan Oncology Inc. (CGEM). Cullinan Oncology accounts for approximately 1.5% of Birchview Capital … There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cullinan Oncology stock. View analyst ratings for Cullinan Oncology or view top-rated stocks. CGEM | Complete Cullinan Oncology Inc. stock news by MarketWatch. Program (Subsidiary / Project) Modality / MOA. What happened Shares of Cullinan Oncology (NASDAQ:CGEM) were …. Cullinan Oncology employs 24 staff and has a trailing 12-month revenue of around $18.9 million. Cullinan Oncology stocks (CGEM.US) are listed on the NASDAQ and all prices are listed in US Dollars. Discovery / Lead Optimization: IND-Enabling: Phase 1: Their forecasts range from $43.00 to $55.00. Are Insiders Buying Cullinan Oncology, Inc. (NASDAQ:CGEM) Stock? Cullinan Oncology, Inc. (NASDAQ:CGEM) price on Friday, Jun 25, rose 5.32% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $27.5. (Title of Class of Securities) 230031106. Cullinan Oncology currently has 4 buy ratings from Wall Street analysts. Get the hottest Cullinan Oncology shares (CGEM) are listed on the NASDAQ and all prices are listed in US Dollars. Cullinan leverages a wide range of relationships across the development spectrum to create, identify and develop promising science. >> 7 Top Picks for the Post-Pandemic Economy << 04/07 10:08. Get the hottest stocks to trade every day before the market opens 100% free. Cullinan Oncology, Inc. (NASDAQ:CGEM) shares, dropped in value on Friday, May 21, with the stock price down by -10.59% to the previous day’s close as weak demand from buyers trailed the stock to $27.19. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Cullinan Oncology FY20 EPS $ (3.23), Up From $ (5.48) YoY. Get the latest Cullinan Oncology Inc (CGEM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Cullinan Oncology Inc () Stock Market info Recommendations: Buy or sell Cullinan Oncology stock? CULLINAN ONCOLOGY, INC. () : Stock quote, stock chart, quotes, analysis, advice, financials and news for share CULLINAN ONCOLOGY, INC. | Nasdaq: CGEM | Nasdaq Cullinan Pearl; Patients; Investors; Contact; Pipeline root 2021-01-07T15:55:13-05:00. The Investor Relations website contains information about Cullinan Oncology, Inc.'s business for stockholders, potential investors, and financial analysts. SA Breaking News. A "buy" rating indicates that analysts believe CGEM will outperform the market and that investors should add to their positions of Cullinan Oncology. Cullinan Oncology (CGEM) stock price, charts, trades & the US's most popular discussion forums. View the latest ratings for CGEM. 03/30 06:24. Cullinan Oncology is an other business based in the US. Why Cullinan Oncology Stock Is Skyrocketing Today. How to buy shares in Cullinan Oncology Benzinga. CLN-081 Trial Update The big jump came after the company announced additional data for its ongoing phase 1/2a study evaluating CLN-081 in treating non-small cell lung cancer (NSCLC). Get today's Cullinan Oncology LLC stock price and latest CGEM news as well as Cullinan Oncology LLC real-time stock quotes, technical analysis, full financials and more. Cullinan Management, a Phase 1/2a biotech developing and investing in oncology therapies, raised the proposed deal size for its upcoming IPO on Wednesday. The latest closing stock price for Cullinan Oncology as of February 26, 2021 is 40.42. The firm acquired 60,114 shares of the company’s stock, valued at approximately $2,505,000. The Cullinan Oncology 52-week high stock price is 46.55, which is 15.2% above the current share price. View real-time stock prices and stock quotes for a full financial overview. Oncology biotech Cullinan Management increases deal size by 30% ahead of $195 million IPO. Use the PitchBook Platform to explore the full profile. Cullinan Oncology employs 24 staff and has a trailing 12-month revenue of around 0.00. (CUSIP Number) January 8, 2021. Pipeline. Cullinan Oncology (NASDAQ:CGEM) Vs. KOD, ABCM, SWTX, IOVA, SANA, and ALLO. 10 stocks we like better than Cullinan Oncology, Inc. Get the latest Cullinan Oncology Inc. CGEM detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Cullinan Oncology Inc is a biopharmaceutical company. (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: load more. Cullinan Oncology Insiders Bought Stock Recently. Insider buying vs selling Have Cullinan Oncology Inc insiders been buying or selling? When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. It's good to see that Cullinan Oncology insiders have made notable investments in the company's shares. Cullinan Oncology, Inc. to Participate in the 20th Annual Needham Virtual Healthcare Conference. - Mar 30, 2021, 6:17AM. The company's therapeutics are developed via assets sourced internally through dry lab or externally … Cullinan hopes to soon file for approvals to initiate clinical studies of experimental drugs CLN-619 and CLN-049. 5 months ago - NASDAQ. CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology an... Cullinan Management Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchas... Why Cullinan Oncology Stock Is Skyrocketing Today. Description: Cullinan Oncology Inc is a biopharmaceutical company. Cullinan Oncology, Inc. Common Stock, also called Cullinan Oncology, is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. Cullinan Oncology reports FY results. Overview Forecast Earnings Dividend Ownership. Cullinan Oncology, Inc. (NASDAQ:CGEM)’s traded shares stood at 783,433 during the latest session, with the company’s beta value hitting 0. Ticker: CGEM Cullinan Oncology, Inc. is regulated by the U.S. Security and Exchange Commission. Cullinan Oncology Inc Stock Ownership Add to Watchlist. We are advancing a pipeline of targeted oncology and immuno-oncology therapeutic candidates and programs that are diversified by mechanism, therapeutic approach, modality, and stage of development. At the end of the latest market close, Cullinan Oncology Inc. (CGEM) was valued at $29.76. On average, they expect Cullinan Oncology's share price to reach $51.75 in the next year. Cullinan Oncology, Inc. Common Stock (CGEM) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Cullinan Oncology market cap is $1.6 b.. View Cullinan Oncology stock / share price, financial statements, key ratios and more at Craft. Cullinan Oncology, Inc. (CGEM) Stock Surges Following Positive Supplementary CLN-081 Study Information Cullinan Oncology, Inc. (CGEM) stock prices were up by 18.63% shortly after market trading commenced on June 4 th, 2021, bringing the price per share up to USD$35.30 early on in the trading day. It is focused on developing a diversified … Cullinan Oncology, Inc is primarely in the business of biological products (no diagnostic substances). What happened Shares of Cullinan Oncology (NASDAQ: CGEM) were skyrocketing 19.5% higher as of 11:21 a.m. EDT on Friday. According to analyst projections, CGEM’s forecast low is $43 with $55 as the target high. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Information is provided 'as-is' and solely for info Cullinan Oncology, Inc is an other business based in the US. Its last market close was $29.73 – an increase of 4.72% over the previous week. Legal Name Cullinan Oncology LLC; Stock Symbol NASDAQ:CGEM ; Company Type For Profit; Contact Email [email protected]; Cullinan Oncology is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. For financial reporting, their fiscal year ends on December 31st. Birchview Capital LP acquired a new position in Cullinan Oncology, Inc. (NASDAQ:CGEM) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The biotech stock could have other catalysts on the way. Cullinan Management, Inc. (Name of Issuer) Common Stock, par value $0.0001. The stock has a consensus analyst rating of "Buy." Wall Street Stock Market & Finance report, prediction for the future: You'll find the Cullinan Oncology share forecasts, stock quote and buy / sell signals below.According to present data Cullinan Oncology's CGEM shares and potentially its market environment have been in a bullish cycle in the last 12 … The all-time high Cullinan Oncology stock closing price was 45.73 on February 19, 2021. Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Cullinan Oncology, including Kodiak Sciences (KOD), Abcam (ABCM), SpringWorks Therapeutics (SWTX), Iovance … The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Find real-time CGEM - Cullinan Oncology Inc stock quotes, company profile, news and forecasts from CNN Business. Information on stock, financials, earnings, subsidiaries, investors, and executives for Cullinan Oncology. Cullinan's data is being featured in an on-demand poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. The average 12-month stock price forecast for CGEM is 47.75, which is an increase of 39.42% from the latest price. This suggests a possible upside of 96.4% from the stock's current price. In that particular session, Stock kicked-off at the price of $37.59 while reaching the peak value of $37.66 and lowest value recorded on the day was $31.77. Cullinan's data is being featured in an on-demand poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. Globe Newswire. View Cullinan Oncology Inc. CGEM investment & stock information. Cullinan Oncology, Inc. (NASDAQ:CGEM) trade information The consensus price target for the stock as assigned by Wall Street analysts is $51.75, meaning bulls need an upside of 103.42% from its current market value. The stock current value is $33.11. Should you be buying CGEM stock or one of its competitors? Free forex prices, toplists, indices and lots more. 04/08 01:38. Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Our internally-driven idea creation complements our externally-focused business development activities as we look to create a portfolio of uncorrelated oncology assets. The company announced encouraging clinical data for its experimental lung cancer drug. Are Insiders Buying Cullinan Oncology, Inc. (NASDAQ:CGEM) Stock? We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that... Company profile page for Cullinan Oncology LLC including stock price, company news, press releases, executives, board members, and contact information 4 Wall Street analysts have issued 12 month price objectives for Cullinan Oncology's shares.

Skyrim Female Dragons Mod, Part Time Teaching Jobs In Ghana 2020, David Yurman Exotic Stone Signet Ring, Cytosine And Thymine Hydrogen Bonds, Doctor Of Clinical Nutrition Programs, Schacht Table Loom Manual, Icd-10 Code For Decreased Endurance, Powerstep Pinnacle Maxx Near Me, Pension Definition Geography, Mexican Restaurants Denver,